Literature DB >> 11225954

Pharmacotherapy of spasticity: oral medications and intrathecal baclofen.

L E Krach1.   

Abstract

Spasticity is a common problem in children with neurologic impairment, particularly in those with cerebral palsy. Clinicians commonly make use of oral medications to attempt to reduce spasticity and increase function. Little has been published in the literature concerning the use of these medications in children and their effects on both muscle tone and function. This article is a review of the sites of action, side effects, and efficacy of benzodiazepines, baclofen, dantrolene sodium, alpha2-adrenergic agonists, and gabapentin. A brief review of intrathecal baclofen is included as well.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11225954     DOI: 10.1177/088307380101600106

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  20 in total

1.  Development of AMPA receptor and GABA B receptor-sensitive spinal hyper-reflexia after spinal air embolism in rat: a systematic neurological, electrophysiological and qualitative histopathological study.

Authors:  Osamu Kakinohana; Miriam Scadeng; Jose A Corleto; Juraj Sevc; Nadezda Lukacova; Martin Marsala
Journal:  Exp Neurol       Date:  2012-06-18       Impact factor: 5.330

Review 2.  Preclinical models of muscle spasticity: valuable tools in the development of novel treatment for neurological diseases and conditions.

Authors:  Anton Bespalov; Liudmila Mus; Edwin Zvartau
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-02-10       Impact factor: 3.000

Review 3.  Pharmacologic interventions for reducing spasticity in cerebral palsy.

Authors:  Dilip R Patel; Olufemi Soyode
Journal:  Indian J Pediatr       Date:  2005-10       Impact factor: 1.967

4.  Antispasmodic medications may be associated with reduced recovery during inpatient rehabilitation after traumatic spinal cord injury.

Authors:  Eric R Theriault; Vincent Huang; Gale Whiteneck; Marcel P Dijkers; Noam Y Harel
Journal:  J Spinal Cord Med       Date:  2016-11-14       Impact factor: 1.985

5.  Pharmacokinetic evaluation of oral dantrolene in the dog.

Authors:  J L Haraschak; V C Langston; R Wang; C Riggs; C Fellman; M K Ross; C Bulla; K Lunsford; A Mackin; T Archer
Journal:  J Vet Pharmacol Ther       Date:  2013-11-13       Impact factor: 1.786

6.  Reduction of spinal sensory transmission by facilitation of 5-HT1B/D receptors in noninjured and spinal cord-injured humans.

Authors:  Jessica M D'Amico; Yaqing Li; David J Bennett; Monica A Gorassini
Journal:  J Neurophysiol       Date:  2012-12-05       Impact factor: 2.714

Review 7.  A benefit-risk assessment of baclofen in severe spinal spasticity.

Authors:  Alessandro Dario; Giustino Tomei
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

8.  Treatment options in pediatric GERD.

Authors:  Neelesh A Tipnis; Colin D Rudolph
Journal:  Curr Treat Options Gastroenterol       Date:  2007-10

Review 9.  Nonoperative management of spasticity in children.

Authors:  Susan Ronan; Joan T Gold
Journal:  Childs Nerv Syst       Date:  2007-07-24       Impact factor: 1.475

10.  Diffusion tensor imaging in children with periventricular leukomalacia: variability of injuries to white matter tracts.

Authors:  L M Nagae; A H Hoon; E Stashinko; D Lin; W Zhang; E Levey; S Wakana; H Jiang; C C Leite; L T Lucato; P C M van Zijl; M V Johnston; S Mori
Journal:  AJNR Am J Neuroradiol       Date:  2007-08       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.